Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 32 | 2024 | 206 | 5.310 |
Why?
|
| Severity of Illness Index | 9 | 2015 | 1801 | 0.850 |
Why?
|
| Sjogren's Syndrome | 4 | 2020 | 30 | 0.610 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 299 | 0.520 |
Why?
|
| Patient Preference | 2 | 2014 | 105 | 0.510 |
Why?
|
| Biological Factors | 1 | 2014 | 18 | 0.510 |
Why?
|
| Autoantibodies | 9 | 2020 | 267 | 0.510 |
Why?
|
| Health Status | 4 | 2013 | 360 | 0.480 |
Why?
|
| Antirheumatic Agents | 2 | 2012 | 54 | 0.470 |
Why?
|
| Tachycardia | 1 | 2013 | 35 | 0.450 |
Why?
|
| Lupus Nephritis | 4 | 2024 | 78 | 0.440 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 379 | 0.430 |
Why?
|
| Interferon-alpha | 7 | 2012 | 233 | 0.430 |
Why?
|
| Patient Care Planning | 1 | 2012 | 81 | 0.420 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 102 | 0.410 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 115 | 0.400 |
Why?
|
| Minority Groups | 1 | 2012 | 137 | 0.390 |
Why?
|
| Adult | 25 | 2024 | 25648 | 0.330 |
Why?
|
| Cognition Disorders | 3 | 2015 | 236 | 0.330 |
Why?
|
| Sick Leave | 1 | 2008 | 13 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 2271 | 0.320 |
Why?
|
| Rheumatology | 1 | 2007 | 28 | 0.310 |
Why?
|
| Blood Viscosity | 1 | 2007 | 16 | 0.310 |
Why?
|
| Specialization | 1 | 2007 | 65 | 0.310 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 62 | 0.300 |
Why?
|
| Decision Making | 1 | 2012 | 642 | 0.280 |
Why?
|
| Female | 30 | 2024 | 44532 | 0.280 |
Why?
|
| Career Choice | 1 | 2007 | 139 | 0.280 |
Why?
|
| Injections | 1 | 2006 | 109 | 0.280 |
Why?
|
| Male | 26 | 2024 | 40965 | 0.260 |
Why?
|
| Physical Examination | 1 | 2006 | 149 | 0.260 |
Why?
|
| Middle Aged | 18 | 2024 | 25028 | 0.260 |
Why?
|
| Disabled Persons | 1 | 2006 | 67 | 0.260 |
Why?
|
| Humans | 40 | 2024 | 86643 | 0.250 |
Why?
|
| Thrombosis | 1 | 2007 | 296 | 0.240 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 3 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2018 | 2357 | 0.240 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 502 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 1621 | 0.230 |
Why?
|
| Muromonab-CD3 | 1 | 2002 | 69 | 0.220 |
Why?
|
| Arthritis, Psoriatic | 1 | 2002 | 32 | 0.220 |
Why?
|
| Internal Medicine | 1 | 2006 | 347 | 0.210 |
Why?
|
| Quality of Life | 3 | 2012 | 1585 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 270 | 0.210 |
Why?
|
| Chicago | 4 | 2014 | 1379 | 0.200 |
Why?
|
| Osteopontin | 2 | 2011 | 47 | 0.190 |
Why?
|
| Internship and Residency | 2 | 2007 | 1004 | 0.190 |
Why?
|
| B-Lymphocytes | 4 | 2018 | 724 | 0.180 |
Why?
|
| Prevalence | 4 | 2016 | 1239 | 0.180 |
Why?
|
| Pain Measurement | 3 | 2006 | 321 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 508 | 0.170 |
Why?
|
| Antibodies, Antinuclear | 4 | 2020 | 83 | 0.170 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 81 | 0.160 |
Why?
|
| Illinois | 2 | 2012 | 462 | 0.160 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2018 | 37 | 0.160 |
Why?
|
| Risk Factors | 5 | 2014 | 5417 | 0.160 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2018 | 109 | 0.160 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 610 | 0.150 |
Why?
|
| Adolescent | 8 | 2024 | 8981 | 0.150 |
Why?
|
| Inflammation | 4 | 2020 | 920 | 0.150 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 1 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 557 | 0.140 |
Why?
|
| Phenotype | 5 | 2020 | 2378 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 29 | 0.140 |
Why?
|
| Genome-Wide Association Study | 4 | 2012 | 1621 | 0.140 |
Why?
|
| Comorbidity | 2 | 2013 | 943 | 0.140 |
Why?
|
| Gene Expression | 1 | 2020 | 1284 | 0.130 |
Why?
|
| Young Adult | 7 | 2024 | 5976 | 0.130 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2015 | 11 | 0.130 |
Why?
|
| Macula Lutea | 1 | 2015 | 19 | 0.130 |
Why?
|
| Nerve Fibers | 1 | 2015 | 46 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2013 | 596 | 0.130 |
Why?
|
| Epitopes | 2 | 2018 | 255 | 0.130 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 294 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 1376 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 977 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 1994 | 52 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 166 | 0.120 |
Why?
|
| Research Subjects | 1 | 2014 | 73 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 1994 | 218 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 132 | 0.110 |
Why?
|
| Tetanus Toxoid | 1 | 2012 | 10 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 351 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 28 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2501 | 0.110 |
Why?
|
| Aged | 7 | 2024 | 18415 | 0.110 |
Why?
|
| Cytokines | 2 | 2020 | 776 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2011 | 30 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2011 | 2767 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 142 | 0.100 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 47 | 0.100 |
Why?
|
| Cicatrix | 1 | 2011 | 63 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 62 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 204 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 293 | 0.100 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2010 | 40 | 0.100 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 2 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2012 | 220 | 0.100 |
Why?
|
| Anxiety | 1 | 2013 | 287 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2024 | 7993 | 0.090 |
Why?
|
| Self Report | 1 | 2012 | 288 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 937 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 685 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2010 | 94 | 0.090 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2018 | 926 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 579 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 971 | 0.090 |
Why?
|
| Chemokine CXCL13 | 2 | 2020 | 15 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 814 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 262 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2010 | 160 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1169 | 0.080 |
Why?
|
| Depression | 1 | 2013 | 473 | 0.080 |
Why?
|
| Genetic Linkage | 1 | 2010 | 623 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 170 | 0.080 |
Why?
|
| Marital Status | 1 | 2008 | 40 | 0.080 |
Why?
|
| Kidney | 1 | 2014 | 1241 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2008 | 55 | 0.080 |
Why?
|
| Outpatients | 1 | 2008 | 94 | 0.080 |
Why?
|
| Alleles | 4 | 2011 | 1128 | 0.080 |
Why?
|
| Educational Status | 1 | 2008 | 188 | 0.080 |
Why?
|
| Rheology | 1 | 2007 | 39 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2011 | 1351 | 0.080 |
Why?
|
| Fatigue | 1 | 2008 | 174 | 0.080 |
Why?
|
| Urban Population | 1 | 2008 | 213 | 0.070 |
Why?
|
| Registries | 1 | 2010 | 702 | 0.070 |
Why?
|
| Interleukins | 2 | 2020 | 134 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1384 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2006 | 91 | 0.070 |
Why?
|
| Nephritis | 1 | 2005 | 20 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2006 | 49 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2006 | 194 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1823 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 6509 | 0.060 |
Why?
|
| Shoulder Joint | 1 | 2006 | 90 | 0.060 |
Why?
|
| Knee Joint | 1 | 2006 | 168 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2006 | 181 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2006 | 297 | 0.060 |
Why?
|
| Education, Medical | 1 | 2007 | 233 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1019 | 0.060 |
Why?
|
| Autoantigens | 2 | 2018 | 127 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2006 | 225 | 0.060 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 1673 | 0.060 |
Why?
|
| Sex Factors | 3 | 2010 | 1054 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2024 | 87 | 0.060 |
Why?
|
| Linear Models | 1 | 2004 | 421 | 0.050 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 241 | 0.050 |
Why?
|
| Genotype | 3 | 2011 | 1851 | 0.050 |
Why?
|
| Ribonucleoproteins | 2 | 2011 | 38 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 3640 | 0.050 |
Why?
|
| DNA | 3 | 2011 | 1294 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 916 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 7 | 0.050 |
Why?
|
| B-Cell Activating Factor | 1 | 2020 | 5 | 0.050 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 4 | 0.050 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 14 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2006 | 751 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 17 | 0.050 |
Why?
|
| Interferons | 1 | 2020 | 133 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1565 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 376 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1805 | 0.040 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2018 | 29 | 0.040 |
Why?
|
| Complement C1q | 1 | 2018 | 10 | 0.040 |
Why?
|
| Malaria | 1 | 2018 | 23 | 0.040 |
Why?
|
| snRNP Core Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1961 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 154 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 296 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 193 | 0.040 |
Why?
|
| Cell Line | 2 | 2012 | 2468 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 476 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 152 | 0.040 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 19 | 0.040 |
Why?
|
| Haplotypes | 1 | 2018 | 642 | 0.040 |
Why?
|
| Trisomy | 1 | 2016 | 55 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 574 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 456 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 55 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 173 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 71 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 207 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 348 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 75 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 43 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 130 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 364 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 194 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 813 | 0.030 |
Why?
|
| United States | 2 | 2018 | 6672 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1994 | 912 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 678 | 0.030 |
Why?
|
| Algorithms | 2 | 2010 | 1830 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2011 | 19 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1195 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2011 | 10 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 92 | 0.030 |
Why?
|
| Feedback | 1 | 2012 | 133 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 203 | 0.020 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2010 | 14 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 528 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 213 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1186 | 0.020 |
Why?
|
| Germinal Center | 1 | 2010 | 55 | 0.020 |
Why?
|
| Aminopeptidases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 183 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2010 | 80 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 129 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 78 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 164 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 116 | 0.020 |
Why?
|
| Pain | 1 | 2012 | 391 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 260 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2010 | 250 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 272 | 0.020 |
Why?
|
| Child | 2 | 2010 | 6927 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 966 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 444 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 999 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 677 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 819 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 758 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2062 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2330 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 930 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1994 | 4213 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3030 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2705 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1851 | 0.020 |
Why?
|
| Infant | 1 | 2010 | 3046 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 3612 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1920 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1994 | 8489 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3241 | 0.010 |
Why?
|